quinoxalines has been researched along with idelalisib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baars, JW; de Rooij, MF; Egile, C; Eldering, E; Jansen, MH; Kater, AP; Kersten, MJ; Kuijpers, TW; Kuil, A; Spaargaren, M; Ter Burg, J; Thijssen, R; van Bochove, GG; van Oers, MH; Virone-Oddos, A | 1 |
| Barata, JT; Bertaina, A; Buontempo, F; Cappellini, A; Chiarini, F; Evangelisti, C; Fragoso, R; Locatelli, F; Lonetti, A; Manzoli, L; Martelli, AM; Neri, LM; Oliveira, M; Orsini, E; Pession, A; Simioni, C | 1 |
2 other study(ies) available for quinoxalines and idelalisib
| Article | Year |
|---|---|
The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.
Topics: Adolescent; Adult; CD40 Antigens; Cell Adhesion; Cell Proliferation; Cell Survival; Cytokines; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Purines; Quinazolinones; Quinoxalines; Sulfonamides; T-Lymphocytes; TOR Serine-Threonine Kinases | 2016 |
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Child; Child, Preschool; Class I Phosphatidylinositol 3-Kinases; Dexamethasone; Glucocorticoids; Heterocyclic Compounds, 3-Ring; Humans; Isoquinolines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-akt; Purines; Quinazolinones; Quinoxalines; Thiazolidinediones; Triazines | 2018 |